Dermatology · Corbin, KY
NPI
1821074360
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1101 Master St
Corbin, KY, 40701
Phone (606) 528-2881
Groups this clinician bills Medicare through
Medicare paid, 2024
$202K
3,095 services
Medicare patients, 2024
986
Average age 74
Drug cost, 2024
$9.2M
8,033 prescriptions
Company payments, 2025
$245K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Melissa L Knuckles was code 99213 (office e&m - established), 862 times for 650 patients. In total Melissa L Knuckles billed 3,095 services in 56 codes, and Medicare paid $202K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 862 | 650 | $60.63 | $52K |
| 17004 Destruction Skin Lesion | Office | 505 | 371 | $102.58 | $52K |
| 99212 Office E&M - Established | Office | 397 | 284 | $38.89 | $15K |
| 99203 Office E&M - New | Office | 272 | 271 | $73.50 | $20K |
| 17003 Destruction Skin Lesion | Office | 264 | 90 | $4.62 | $1,220 |
| 11102 Skin Biopsy | Office | 162 | 151 | $69.55 | $11K |
| 17000 Destruction Skin Lesion | Office | 130 | 123 | $45.47 | $5,911 |
| 11103 Skin Biopsy | Office | 92 | 73 | $35.72 | $3,286 |
| 11106 Skin Biopsy | Office | 81 | 75 | $102.11 | $8,271 |
| 11107 Skin Biopsy | Office | 74 | 51 | $49.92 | $3,694 |
| 12032 Wound Repair - All Levels | Office | 29 | 27 | $198.17 | $5,747 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 28 | 22 | $0.81 | $22.55 |
| 11901 Skin | Office | 25 | 17 | $49.87 | $1,247 |
By year: 2022 $254K for 4,197 services; 2023 $234K for 4,067 services; 2024 $202K for 3,095 services.
Medicare prescription drug claims, 2024
In 2024, the drug Melissa L Knuckles prescribed most often to Medicare patients was Triamcinolone Acetonide, with 1,362 prescriptions and refills. In total Melissa L Knuckles wrote 8,033 Medicare prescriptions that cost $9.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 1,362 | 1,444 | 719 | $7,037 |
| Mupirocin Generic | 810 | 818 | 572 | $4,382 |
| Dupixent Pen Dupilumab | 808 | 831 | 121 | $3.2M |
| Metronidazole Generic | 779 | 838 | 455 | $50K |
| Clobetasol Propionate Generic | 675 | 740 | 360 | $20K |
| Tacrolimus Generic | 351 | 381 | 217 | $53K |
| Hydrocortisone Generic | 280 | 291 | 159 | $1,229 |
| Betamethasone Dipropionate Generic | 279 | 308 | 163 | $11K |
| Doxycycline Hyclate Generic | 164 | 169 | 75 | $2,761 |
| Otezla Apremilast | 162 | 162 | 31 | $776K |
| Adbry Tralokinumab-Ldrm | 160 | 160 | 30 | $606K |
| Hydroxychloroquine Sulfate Generic | 104 | 134 | 25 | $1,953 |
| Clindamycin Hcl Generic | 102 | 105 | 61 | $1,088 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 96 | 96 | 56 | $1,637 |
| Prednisone Generic | 88 | 103 | 51 | $658 |
Brand drugs: 1,919 claims; generic drugs: 6,114 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Melissa L Knuckles $245K ($245K in general payments such as food, travel and fees) from 21 companies. The largest payer was Galderma Laboratories, L.P. with $35K.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 35 | $35K |
| UCB, Inc. UCB.BR | 45 | $31K |
| Regeneron Healthcare Solutions, Inc. REGN | 67 | $28K |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 36 | $24K |
| Botanix SB Inc | 23 | $23K |
| LEO Pharma Inc. | 38 | $22K |
| Organon LLC OGN | 13 | $18K |
| E.R. Squibb & Sons, L.L.C. BMY | 33 | $16K |
| Arcutis Biotherapeutics, Inc. ARQT | 14 | $14K |
| Abbvie Inc. ABBV | 41 | $13K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.